遺傳性慢性阻塞性肺病（COPD）市場：依藥物類別、給藥途徑、通路及地區分類

Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，遺傳性慢性阻塞性肺病(COPD) 市場規模將達到 6.364 億美元，到 2033 年將達到 8.043 億美元。預計 2026 年至 2033 年的複合年成長率為 3.4%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	6.364億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	3.40%	2033年市場規模預測：	8.043億美元

與α1-抗胰蛋白酶缺乏相關的肺氣腫稱為遺傳性慢性阻塞性肺病（COPD），其特徵是肺部炎症，導致肺部氣流受阻。 COPD是一種慢性疾病，症狀包括喘息、痰液增加和呼吸困難。慢性支氣管炎、肺氣腫和難治性氣喘都是COPD的症狀，COPD是退化性肺病。慢性阻塞性肺病（COPD）的主要原因包括吸菸、空氣污染、被動吸菸、α1-抗胰蛋白酶缺乏相關性肺氣腫（一種罕見的COPD類型）以及其他因素。

每年有數百萬人被診斷出患有慢性阻塞性肺病（COPD）。肺氣腫和慢性支氣管炎是兩種統稱為COPD的疾病。肺氣腫會導致肺部肺泡（氣囊）受損。運動時呼吸困難是肺氣腫的首發徵兆。之後，即使在休息時也會出現呼吸困難。慢性阻塞性肺病（COPD）分為四個階段，從輕度到重度不等。症狀包括持續咳嗽、呼吸困難和喘息。

市場動態

市場主要參與者擴大採用有機成長策略，例如產品上市和獲得監管部門批准，預計將在預測期內推動市場成長。例如，2020年9月，製藥公司葛蘭素史克(GSK Plc.)和專注於醫療保健的資產管理公司Innoviva Inc.宣布，美國食品藥物管理局(FDA)批准了Trelezzi Ellipta（Fluticasone氟替卡松/烏美溴銨/Vilanterol，簡稱「FF/UMEC/VI」）的新適應症，用於治療18歲及以上患者的氣喘，擴大了其目前獲批用於治療慢性阻塞性肺病(COPD)患者的範圍。 Trelezzi Ellipta不適用於緩解急性支氣管痙攣。此外，呼吸系統疾病領域還有多種正在研發中的藥物，主要針對COPD，預計這些藥物將促進全球慢性阻塞性肺病(COPD)市場的成長。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數分析了全球遺傳性慢性阻塞性肺病(COPD) 治療市場主要公司的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球遺傳性慢性阻塞性肺病（COPD）治療市場」報告的目標相關人員包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等行業利益相關者。
相關人員可以透過利用分析全球遺傳性慢性阻塞性肺病(COPD) 治療市場所使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
公司簡介
- GSK Plc
- AstraZeneca Plc
- Merck（Sigma-Aldrich）
- Dey Pharma
- Grifols, SA
- Teva Pharmaceutical Industries Ltd
- Baxter
- Boehringer Ingelheim International GmbH
- Kamada Ltd
- Takeda Pharmaceutical Company Limited
- LFB SA
- Abeona Therapeutics
- Alnylam Pharmaceuticals, Inc.
- Vertex Pharmaceuticals Incorporated
- Kedrion SpA
- Arrowhead Pharmaceuticals, Inc

第9章

參考
調查方法

簡介目錄

Product Code: CMI5512

Genetic Chronic Obstructive Pulmonary Disease (COPD) Market is estimated to be valued at USD 636.4 Mn in 2026 and is expected to reach USD 804.3 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 636.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.40%	2033 Value Projection:	USD 804.3 Mn

Alpha-1 deficiency-related emphysema is called as genetic Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic illness, and some of its symptoms include wheezing, mucus production, and breathing difficulties. Chronic bronchitis, emphysema, and refractory asthma are all symptoms of COPD, a degenerative lung condition. Chronic obstructive pulmonary disease (COPD) is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors.

Each year, millions of people are affected by chronic obstructive pulmonary disease, or COPD for short. Emphysema and chronic bronchitis are two conditions that are collectively referred to as COPD. The lungs' alveoli, which are air sacs, suffer damage in emphysema. Breathlessness while exercising is the first sign of emphysema. Later, breathing difficulties can also happen while at rest. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing.

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product launch and approval is expected to drive market growth over the forecast period. For instance, in September 2020, GSK, Plc.,a pharmaceutical company and Innoviva Inc., a healthcare focused asset management company, announced that the U.S. Food and Drug Administration (FDA) approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the treatment of asthma in patients 18 years and older, expanding the current approval for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. Moreover, several prospective drugs, primarily for COPD, are in the pipeline for respiratory illnesses, which is anticipated to boost growth of the global genetic chornic obstructive pulmonary disease (COPD) market.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
it profiles key players in the global genetic chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study GSK Plc., AstraZeneca Plc., Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global genetic chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genetic chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Bronchodilators
Phosphodiesterase Type 4 Inhibitors
Steroids
Antibiotics
Others
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Nasal
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Region/Country
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
GSK Plc*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca Plc
Merck (Sigma-Aldrich)
Dey Pharma
Grifols, S.A.
Teva Pharmaceutical Industries Ltd
Baxter
Boehringer Ingelheim International GmbH
Kamada Ltd
Takeda Pharmaceutical Company Limited.
LFB SA
Abeona Therapeutics
Alnylam Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
Kedrion S.p.A.
Arrowhead Pharmaceuticals, Inc

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Key Highlights
Research and Development Collaboration, Mergers, and Acquisitions
PEST Analysis
Pipeline Analysis
Epidemiology

4. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Steroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Route Of Administration, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Nasal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Distribution Channel, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

7. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- GSK Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck (Sigma-Aldrich)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Dey Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Grifols, S.A.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Baxter
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Boehringer Ingelheim International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Kamada Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Takeda Pharmaceutical Company Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- LFB SA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Abeona Therapeutics
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Alnylam Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Vertex Pharmaceuticals Incorporated
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Kedrion S.p.A.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Arrowhead Pharmaceuticals, Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies